Anti-staphylococcal activities of lysostaphin and LytM catalytic domain by Sabala, Izabela et al.
Sabala et al. BMC Microbiology 2012, 12:97
http://www.biomedcentral.com/1471-2180/12/97RESEARCH ARTICLE Open AccessAnti-staphylococcal activities of lysostaphin and
LytM catalytic domain
Izabela Sabala1,2*, Ing-Marie Jonsson3, Andrej Tarkowski3ˆ and Matthias Bochtler1,2,4Abstract
Background: Lysostaphin and the catalytic domain of LytM cleave pentaglycine crossbridges of Staphylococcus
aureus peptidoglycan. The bacteriocin lysostaphin is secreted by Staphylococcus simulans biovar staphylolyticus and
directed against the cell walls of competing S. aureus. LytM is produced by S. aureus as a latent autolysin and can
be activated in vitro by the removal of an N-terminal domain and occluding region.
Results: We compared the efficacies of the lysostaphin and LytM catalytic domains using a newly developed
model of chronic S. aureus infected eczema. Lysostaphin was effective, like in other models. In contrast, LytM was
not significantly better than control. The different treatment outcomes could be correlated with in vitro properties
of the proteins, including proteolytic stability, affinity to cell wall components other than peptidoglycan, and
sensitivity to the ionic milieu.
Conclusions: Although lysostaphin and LytM cleave the same peptide bond in the peptidoglycan, the two
enzymes have very different environmental requirements what is reflected in their contrasting performance in
mouse eczema model.Background
The problem of growing antibiotic resistance has been
solved only in part by the introduction or reintroduction
of new antibiotics (such as the quinupristin/dalfopristin
Synercid [1] and the oxazolidinones [2]). Peptidoglycan
hydrolases represent an alternative to small molecule anti-
bacterials, despite concerns relating to immunogenicity,
the release of proinflammatory components during bac-
teriolysis and the development of resistance [3]. The pep-
tidoglycan endopeptidases lysostaphin and LytM cleave
the characteristic pentaglycine crossbridges of S. aureus
peptidoglycan [4-6] and are therefore of interest as poten-
tial antistaphylococcal agents.
Lysostaphin (Figure 1) is produced by Staphylococcus
simulans biovar staphylolyticus. The secreted prepropro-
tein is synthesized with a leader sequence, proregion,
catalytic domain, and the cell wall targeting domain
(CWT) [7]. The low complexity proregion consists of a* Correspondence: izabela@iimcb.gov.pl
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reproduction in any medium, provided the orvariable number of stereotypical repeats (sequence
AEVETSKAPVENT)[8]. It can be cleaved off in vivo by
extracellular cysteine protease [9] to release the mature
form, which is often simply called lysostaphin and is
commercially available. Mature lysostaphin consists of
the catalytic and CWT domains. The catalytic domain
belongs to MEROPS family 23 in clan MO [10] and can
be classified with the LAS metallopeptidases [11]. Se-
quence alignments suggest that the single Zn2+ ion in
the active site is coordinated by His279, Asp283 and
His362 (numbering according to Swiss-Prot entry
P10547) and a water molecule. As the name implies, the
CWT domain anchors the protein to cell walls [9]
(Figure 1).
The biological role of lysostaphin is well established.
The (mature) protein is inactive against the producer or-
ganism, but very effective in cleaving S. aureus cell walls
[14]. This property has made the enzyme attractive as an
antibacterial agent [15-21]. The protein has been applied
to disrupt S. aureus and S. epidermidis biofilms on artifi-
cial surfaces [22] and has also been tested as a coating for
catheters [23]. In a mouse model, lysostaphin has been
used to eradicate S. aureus biofilms from a catheterized
jugular vein [24] and also for treatment of systemicLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Domain organization of preprolysostaphin and full-length LytM. (A) Schematic representation of the domain organization of
preprolysostaphin and full-length LytM. The alignment shows the high similarity of the two proteins in the region of the catalytic domain. The
Zn2+ ligands of the mature forms in the Hx3D and HxH motifs are highlighted in bold. Those in the Hx3D motif are separately changed to
alanines in the mutationally inactivated LytM variants. (B) Schematic representation of lysostaphin, LytM, and the LytM fragments that are used
for this study. (C) Overall (top) and active site region (bottom) representations of the three-dimensional structures of preprolysostaphin (left) and
full-length LytM (right). The left overall model was generated by the SWISSPROT server based on PDB entries 1QWY [12] and 1R77 [13]. The
relative orientation of the catalytic and CWT domains is unknown and was chosen arbitrarily. It is not known whether the proregion repeats
assume a defined structure or remain unstructured. The right overall model is an experimental structure directly based on PDB entry 1QWY [12].
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has proven effective in eradicating S. aureus nasal
colonization [26]. In humans, lysostaphin has been used
on an experimental basis to treat methicillin-resistant S.
aureus aortic valve endocarditis [27]. As the elimination
of S. aureus carriage in hospital staff is demonstrablyeffective in reducing infection rates in surgical patients
and those on hemodialysis [28], a lysostaphin cream to
treat infected, but asymptomatic hospital staff, has
potential.
Staphylococcus aureus LytM (Figure 1) is an autolysin
under the control of the two-component system WalKR,
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metabolism [29]. The protein is synthesized with a signal
peptide (LytM1-25), followed by an N-terminal domain
that is homologous to the staphylococcal secretory anti-
gen A (SsaA), another WalKR controlled protein, but
not to the N-terminal domain of lysostaphin. The C-
terminal domain of LytM can be divided into an occluding
region and a region of high similarity to the lysostaphin
catalytic domain (52% amino acid identity over 106 resi-
dues). The lysostaphin active site residues are all con-
served, with a central Zn2+ ion that is coordinated by
His210, Asp214 and His293 of the catalytic domain [12].
Nevertheless, the structure strongly suggests that full
length LytM cannot have significant activity, because the
active site is occluded. The expected water molecule in
the coordination sphere of the Zn2+ ion is displaced by an
“asparagine switch” residue (Asn117) of the occluding re-
gion, which also blocks part of the active site cleft [12].
However, the crystal structure suggested that the catalytic
domain alone should be more active than the full length
protein. This was confirmed for a tryptic fragment
(LytM180-316, previously referred to as in vitro activated
LytM) and for the recombinantly overexpressed catalytic
domain (LytM185-316, previously referred to as active
LytM) [12,30]. In this work, we use the designation “cata-
lytic domain” for the LytM185-316 fragment for consistency
with the well-established lysostaphin nomenclature, even
though the catalytic domain and occluding loop form the
globular unit in the full length protein [12]. LytM lacks a
counterpart for the cell wall targeting domain of lysosta-
phin (Figure 1).
The biological role of LytM is still not clear [31]. The
protein was originally described as an autolysin (detected
in an otherwise autolysin deficient background) [5] and
reported to have glycylglycine endopeptidase activity
[32]. Both we and other investigators have since then
carried out experiments that cast doubt on the peptido-
glycan hydrolyzing activity of full length LytM [12,31].
Nevertheless, the data clearly confirmed such activity of
the catalytic fragment [12,30]. It remains to be determined
whether the LytM catalytic domain can be released under
physiological circumstances. A proteomic study of the S.
aureus cell wall envelope fraction has identified only full
length LytM (with a molecular mass of approximately
40 kDa and a pI around 6), but not in the predicted active
form [33]. Although the physiological role of LytM and its
catalytic domain remains uncertain, the catalytic domain
has properties that could make it attractive as a potential
antistaphylococcal agent. First, the protein can be easily
overexpressed in Escherichia coli with very high yields and
is easy to purify [30]. Moreover, preliminary in vitro experi-
ments indicated that in certain conditions LytM185-316 was
similarly effective as lysostaphin in clearing turbid cell wall
suspensions.Therefore, we proceeded to compare lysostaphin and
LytM in a new mouse model of staphylococcal infection.
The efficacy of lysostaphin was confirmed in the new
model as well. Surprisingly, the catalytic domain of LytM
was no more effective than control. This finding prompted
us to compare properties of the two proteins in greater
detail in vitro. Here, we report the in vivo observations
and the in vitro properties of lysostaphin and LytM that
might explain the different treatment outcomes.
Results
Chronic contact eczema model of staphylococcal infection
A new chronic dermatitis model of staphylococcal infection
for in vivo functional studies was developed. Following
standard procedures, mice were sensitized by epicutaneous
application of 4-ethoxymethylene-2-phenyloxazolone (oxa-
zolone, Sigma) on the abdomen skin. Six days later and
subsequently every second day they were challenged with
oxazolone applied to the ears. The treatment led to the de-
velopment of chronic contact eczema in the treated ear, but
not in the contralateral ear, which was left untreated as a
control (Additional file 1).
Preliminary experiments were run to establish a suit-
able S. aureus dose for the infection experiments. 106,
107, 108, and 109 CFUs of S. aureus strain LS-1 were
spread on both ears of one mouse each. Mice were
sacrificed two days later, ears were homogenized and S.
aureus colony forming units (CFUs) counted. 106 S.
aureus cells per ear were sufficient to establish infection
in oxazolone-treated, inflamed mouse ears, but not in
non-oxazolone treated ears (data not shown).
To establish the time course for the infection, 106 S.
aureus cells were applied to the oxazolone-treated,
inflamed ears and to the non-oxazolone treated, contra-
lateral control ears. At different time points following in-
oculation, mice were sacrificed, ears homogenized and S.
aureus colony forming units (CFUs) counted. In non-
oxazolone treated control ears, no bacteria were found
after the application of 106 S. aureus cells. In oxazolone
pretreated ears, colony counts peaked two days after ex-
posure, and bacteria were almost fully cleared six days
after the inoculation (Figure 2A).
Lysostaphin is effective in the contact eczema model,
LytM185-316 is not
The newly developed eczema model was used for in vivo
comparison of lysostaphin and LytM efficacies. 30 mice
were divided into three groups of 10 mice each. All mice
were sensitized to develop eczema, and subsequently
had 106 CFUs of S. aureus P1 cells applied to their ears
to induce dermatitis. Twelve hours after inoculation of
bacteria the treatment with lysostaphin and LytM185-316
was started. 100 μg of lysostaphin or LytM185-316 in
50 mM glycine pH 8.0 with 10% glycerol was applied
Figure 2 Kinetics of S. aureus infection in mouse model and the
effect of enzyme treatment. Colony forming units (CFUs) after S.
aureus infection. The data are represented in whisker-box plots.
Boxes cover the second and third quartiles, and horizontal lines
indicate medians. (A) Persistence of S. aureus strain LS-1 in
eczematous ears of NMRI mice 1, 2, 3, and 6 days after topical
application of 106 S. aureus LS-1 per ear (n = 4/time point). (B) Effect
of lysostaphin (Lss) and LytM185-316 (LytM) on S. aureus P1 recovery
from infected mice ears as compared to the control. Twelve hours
after inoculation of bacteria on ears with eczema 100 μg of
lysostaphin or LytM185-316 (100ug each) in 50 mM glycine pH 8.0 and
10% glycerol buffer was applied to each mice ear. Ears of control
mice were treated with buffer alone. Treatment was repeated 4
times every 12 hours and ears were examined 3 hours after the last
treatment. The two-tailed Student's t-test (assuming equal variances
in all samples) was used to calculate probabilities for the null
hypothesis of equal means in pairwise comparisons. The resulting
p-values are indicated above the curly brackets.
Figure 3 Pulldown assay with S. aureus cell walls treated in
various ways. Pulldown of (A) lysostaphin, (B) LytM185-316 and (C)
LytM26-316 with S. aureus cell walls treated in various ways. (1) Input,
(2) sonicated crude cell walls, (3) washed crude cell walls, (4) SDS-
treated cell walls, (5) TCA-treated cell walls, (6) trypsinised cell walls,
(7) purified peptidoglycans (8) commercially available
peptidoglycans. The protein that was input (lane 1) or pulled down
(lanes 2–8) was visualized by Western blotting with the anti-LytM
antibody.
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trol group, buffer alone was used for the treatment. Ears
were treated with proteins or buffer four times every 12
hours. Three hours after the last treatment mice were
anesthetized, the ears dissected and the extent of infection
estimated as described above. On average, the lysostaphin
treatment reduced the colony count by roughly a factor of
10. In contrast to lysostaphin, LytM185-316 had no benefi-
cial effect and was no better than control (Figure 2B).
We reasoned that the different treatment outcomes
could reflect differences in protein stability, affinity to ei-
ther peptidoglycan or other components of cell walls, or
the preference for a particular pH or ionic milieu and
proceeded to test the influence of all these factors
in vitro.
Lysostaphin is proteolytically more stable than LytM185-316
During treatment, lysostaphin and LytM185-316 were
exposed both to bacterial proteases and to host proteases
at the site of infection. Initial experiments demonstratedthat both enzymes were stable in bacterial cultures
(CFU ~106). The stability to host enzymes was tested with
blood and serum from rat, which were available from un-
related experiments without the sacrifice of additional ani-
mals. After 4 h incubation in 5% blood, the majority of
LytM185-316 was degraded while the degradation of lysos-
taphin was minimal. Both proteins were more stable in 5%
serum, but again LytM185-316 was less stable than lysosta-
phin (Additional file 2).
Lysostaphin and LytM185-316 recognize different cell wall
components
The affinity of lysostaphin and LytM was compared in a
pulldown assay using various cell wall preparations that
were increasingly enriched in peptidoglycan (Figure 3).
Cell walls were used either crude (lane 2) or subjected to
an extra washing step (lane 3), to SDS treatment, which
should remove lipid components (lane 4), to TCA treat-
ment, which is thought to remove teichoic acids (lane 5),
or to trypsin treatment, which can be expected to re-
move protein components from cell walls (lane 6). The
pulldown assay was also carried out with “purified” pep-
tidoglycan, which was obtained from crude cell wall pre-
parations by a combination of the SDS-, TCA- and
trypsin treatments (lane 7), and with peptidoglycan from
a commercial source (Fluka) (lane 8).
In all cases, lysostaphin bound to the cell wall prepara-
tions albeit with different efficiency. Our results suggest
that binding to crude cell walls was most effective, prob-
ably because of interactions between lysostaphin and
non-peptidoglycan components of S. aureus cell walls
(Figure 3A).
Figure 4 Pulldown assay of various LytM fragments and
inhibitors with purified peptidoglycans from S. aureus. (A) Full
length LytM and various fragments were analyzed by denaturing gel
electrophoresis and Coomassie straining either directly (control, C) or
after separation into peptidoglycan binding (PG) and supernatant (S)
fractions. (B) LytM185-316 was incubated with peptidoglycan in the
presence of various protease inhibitors and the pellet fraction after
pulldown analyzed by denaturing gel electrophoresis and Western
blotting.
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down by crude cell wall preparations. However, when
the cell walls were subjected to a washing step prior to
the pulldown experiment, LytM185-316 could be effect-
ively pulled down. The effect of the washing step on the
cell wall preparations is not clear. It may simply reduce
clumping and make cell wall structures more accessible.
Alternatively it may remove a putative inhibitory factor
in the unwashed cell wall sonicate. Further purification
of peptidoglycan had a little effect on the outcome of
the pulldown experiments. Therefore, we conclude that
LytM185-316 binds directly to cell walls and interacts pri-
marily with peptidoglycans, rather than with other cell
wall components (Figure 3B).
Full length LytM (without predicted signal peptide,
LytM26-316) was not efficiently pulled down by any of the
peptidoglycan preparations. Traces of protein were
detected in the pulldown fraction in some cases, but the
effect was probably unspecific, because no systematic
trend with increasing peptidoglycan purity was observed
(Figure 3C).
Lysostaphin and LytM185-316 bind peptidoglycan or cell
walls differently
The involvement of different regions of lysostaphin in
peptidoglycan binding has been investigated earlier. The
results show that lysostaphin has affinity for the penta-
glycine crossbridges themselves [34], but also binds cell
walls via the cell wall targeting domain [35]. In contrast,
almost nothing is known about the role of different LytM
fragments in peptidoglycan binding. Therefore, we investi-
gated this question by the pulldown assay (Figure 4A).
Comparing the amounts of protein in the pulldown and
supernatant fractions, we found that the full length pro-
tein (LytM26-316) did not efficiently bind to peptidoglycan.
Mutation of the Zn2+ ligand Asn117 to alanine, which
should weaken the binding of the occluding region to the
catalytic domain, did not significantly change the situ-
ation. The isolated N-terminal domain of the enzyme also
failed to bind to peptidoglycan, whereas LytM185-316
bound efficiently. When the two Zn2+ ligands His210 and
Asp214 were separately mutated to alanine, the binding
was lost again. Changing the third Zn2+ ligand, His293 of
the HxH motif to alanine, made the protein insoluble as
reported earlier [12], so that peptidoglycan binding could
not be tested. The first histidine of the HxH motif,
His291, is likely to act as a general base in catalysis [11].
When this residue was mutated to alanine, peptidoglycan
binding was reduced, but not fully abolished.
The requirement of an intact active site for peptidogly-
can binding was also supported by inhibitor studies. We
had previously shown that EDTA and 1,10-phenanthroline
blocked activity, presumably by chelating Zn2+ ions. We
now observed that both metal chelators also abolishedbinding of LytM185-316 to peptidoglycan (Figure 4B, lanes
1–2). In contrast, the weak Zn2+ ion chelator glycine
hydroxamate and other small molecules and protease
inhibitors did not interfere with peptidoglycan binding
(Figure 4B, lanes 3–6). We conclude from these experi-
ments that the accessibility and integrity of the active site
is essential for the binding of the protein to peptidoglycan
(Figure 4).
Lysostaphin and LytM185-316 activities depend differently
on pH
Peptidoglycan hydrolase activities were assayed in a tur-
bidity clearance assay, using S. aureus cells. Perhaps due
to remaining peptidoglycan hydrolase activity in the cell
wall, there was some decrease of turbidity also in control,
in the absence of exogenously added enzyme. Therefore,
all apparent OD values at 595 nm were expressed as
Figure 6 Effect of various buffers on lytic activity of lysostaphin
and LytM185-316. Lysis by lysostaphin (closed squares) and LytM185-
316 (open squares) was done in following buffers: (1) dd water, (2)
glycine-NaOH, (3) D,L-alanine-NaOH, (4) diglycine-NaOH, (5) bicine-
NaOH, (6) triglycine-NaOH, (7) Tris-HCl, (8) hepes-NaOH, (9)
phosphate buffer, (10) L-arginine-HCl, (11) L-glutamic acid-NaOH,
(12) diaminopimelic acid-NaOH. All buffers were 50 mM with pH
adjusted to 8.0 and data were collected after 60 min of reaction.
Sabala et al. BMC Microbiology 2012, 12:97 Page 6 of 11
http://www.biomedcentral.com/1471-2180/12/97percent of the control. A value close to 100% indicates a
very low activity, whereas a very low OD reports highly ac-
tive enzyme. Both lysostaphin and LytM185-316 were only
marginally effective at pH 6.0 (50 mM phosphate buffer),
but became much more active at pH 7.0. A further pH in-
crease to the range between 7.0 and 9.0 (50 mM Tris–HCl)
had little effect on the activity of lysostaphin, but enhanced
the activity of LytM185-316. Even at pH 9.0, incubation with
LytM185-316 lysed fewer cells than incubation with the
equivalent amount of lysostaphin, particularly at late time
points, possibly because of the lower stability of LytM185-316
(Figure 5).
Lysostaphin and LytM185-316 activities depend very
differently on ionic strength
Investigating the pH dependence, we noticed a dramatic
dependence of the lysis efficiency on the buffer. For ex-
ample, the activity of LytM185-316 was much higher in
20 mM than in 50 mM Tris–HCl (both pH 8.0), and
increased further when Tris was replaced with glycine at
pH 8.0. However, glycine did not seem to act as an allo-
steric activator, because it did not enhance the activity
when it was added in the presence of other buffer sub-
stances. Similar observations were made with other buf-
fer components (Additional file 3).
A clear pattern emerged only when lysis activities of
LytM185-316 and lysostaphin were correlated with the con-
ductivity of the buffers (Figure 6). Lysostaphin degrades S.
aureus cell walls inefficiently in low conductivity buffers,Figure 5 Effect of buffer pH on lytic activity of lysostaphin and
LytM185-316. Activity of lysostaphin (solid lines) and LytM185-316
(dotted lines) in 50 mM Tris buffer at pH 7.0 (squares), 8.0 (circles)
and 9.0 (triangles). S. aureus cells were collected in the exponential
growth phase, washed and resuspended in test buffer to apparent
OD595 ~1.8. The addition of LytM185-316 or lysostaphin (both at
18 nM final concentration) led to cell lysis, which reduced light
scattering and thus apparent OD595. As some decrease was also
observed in the absence of enzyme, all OD595 values were expressed
as percent of the control without enzyme.but becomes more efficient in buffers of higher conductiv-
ity. In contrast, LytM185-316 works best at low conductiv-
ity, and is almost ineffective in high conductivity buffers.
The transition region for both effects is around 2 mS/cm,
which corresponds roughly to a total ion concentration of
15–20 mM for singly charged cations and anions and typ-
ical mobilities (Figure 6).
Conductivity reflects both ion concentration and mobil-
ity. We reasoned that ionic strength was more likely than
conductivity to influence protein activity, and therefore
varied conductivity systematically by changing the concen-
tration of sodium chloride between 0 and 500 mM. Lysos-
taphin and LytM185-316 activities were again dependent on
the ionic strength in the expected manner, but conductiv-
ity was more directly correlated with ionic strength in this
experiment (Figure 7).
The influence of ionic strength could also be demon-
strated in a different way that was more directly related
to the in vivo experiments. The low lytic efficiency of
lysostaphin in glycine buffer could be overcome by
addition of 25 to 100% of serum. Conversely, the addition
of 25% or more serum to optimal reaction conditions for
LytM185-316 (50 mM glycine-NaOH) completely abolished
the activity of enzyme (data not shown).
The analysis of MIC and MBC for lysostaphin and
LytM185-316 confirmed the above conclusions. The MIC
for lysostaphin was around 0.0015-0.003 μg/ml, but in-
hibition of bacterial growth was not observed even with
5 μg/ml of LytM185-316. The MBC of lysostaphin was ap-
proximately 0.15 μg/ml in CASO broth and glycine buf-
fer in agreement with previous data [36]. LytM185-316
Figure 7 The effect of ionic strength of reaction buffer on lytic
activity of lysostaphin and LytM185-316. Lysis was done in
standard conditions (see Material and Methods) in 20 mM glycine
buffer pH 8.0 supplemented with 0 to 500 mM NaCl. Conductivity of
the reaction was measured at room temperature after addition of S.
aureus cells. Presented results were collected after 60 min of lysis
reaction at 37°C.
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glycine buffer, but did not exhibit bactericidal activity in
CAMH or CASO broth growth media which have con-
ductivity 18 mS/cm.
Discussion
Lysostaphin treatment of S. aureus infection has been
reported earlier. In a cotton rat model, S. aureus nasal
colonization has been eradicated by this enzyme [26]. In
the mouse, S. aureus systemic infections have been suc-
cessfully treated [25] and biofilms have been effectively
eliminated from a catheterized jugular vein [24]. The
chronic dermatitis model of staphylococcal infection
reported in this paper differs significantly from the earl-
ier models and therefore represents an independent con-
firmation for the efficacy of lysostaphin. The lack of
efficacy of the LytM185-316 treatment was initially surpris-
ing in light of previously observed comparable activity of
lysostaphin and LytM185-316, though in experiments car-
ried out in low salt buffers. As a result of this work, we
now know that LytM185-316 differs from lysostaphin in sev-
eral ways that could all explain the outcome of the mouse
experiments.
Stability
LytM185-316 is a very stable protein in extracts of
Escherichia coli, where the protein can be effectively
produced recombinantly. The protein is also stable
against staphylococcal proteases, just like lysostaphin.
However, there are stability differences in serum and
blood. This would obviously be relevant if lysostaphin or
LytM were used systemically. As we are not sure to what
extent the proteolytic stabilities in blood or serum reflect
the situation in tissues with eczema, the influence of thisfactor on the overall treatment income is not clear
though should not be neglected.
Binding
Both lysostaphin and LytM185-316 bind the pentaglycine
crossbridges of S. aureus peptidoglycan. Both proteins
recognize the crossbridges themselves, probably at least
in part by interactions with the active site cleft. Lysosta-
phin has an extra cell wall targeting (CWT) domain
which provides affinity. There is no counterpart in LytM
(or LytM185-316), and therefore we originally expected
that the N-terminal domain of the full length protein
might play a similar role, especially in the light of the
homology to SsaA. However, our experiments argue
against this possibility, because full length LytM does
not bind peptidoglycan.
Modular structure
LytM185-316 binds purified peptidoglycan the most ef-
fectively. The opposite is true for lysostaphin, which
seems to recognize other cell wall components as
well. It has previously been reported that deletion of
the CWT domain in lysostaphin does not interfere
with the endopeptidase activity of the enzyme, but
abolishes its ability to distinguish between S. aureus
and S. staphylolyticus [37]. As the peptidoglycans of
the two bacterial species are identical [38], it suggests
the recognition of non-cell wall components by CWT.
Irrespective of which part of the lysostaphin protein
provides the affinity to non-peptidoglycan cell walls,
the ability of the protein to bind to crude cell walls is
clearly helpful to lyse intact cells and seems to pro-
vide lysostaphin with an advantage as a protein drug.
LytM is an autolysin, which is produced by the cell
and delivered to the cell wall from “inside” while
lysostaphin is a bacteriocin that approach target cells
from the “outside”. In the treatment model, the ap-
proach of the peptidoglycan hydrolases to cell walls is
necessarily from the outside, again favouring lysosta-
phin over any LytM fragment.
Ionic milieu
Perhaps the most crucial factor to explain the different
treatment outcomes is the very different response of the
two proteins to the ionic milieu. We do not know the
precise ionic milieu of the contact eczema model of S.
aureus infection, but suspect that it belongs to the high
ionic strength regime, which would certainly apply for
serum. If this is true, the ionic milieu in the mouse ec-
zema could explain differences in treatment outcomes
between lysostaphin preferring higher concentrations of
salts for its activity and LytM being strongly inhibited in
such environment.
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Perhaps the strongest predictor of the mouse experi-
ments is the biology of lysostaphin and LytM. As a bac-
teriocin, lysostaphin is evolved for the lysis of S. aureus
cell walls. In contrast, LytM as an autolysin should be
evolved to have its activity under tight control. We
expected this to apply for the full length enzyme, but
hoped to bypass this step by the artificial activation that
removes the N-terminal domain and the occluding re-
gion. Apparently, this does not suffice, because there are
differences at several other levels which reflect the dif-
ferent in vivo roles of lysostaphin and LytM. We con-
clude that the use of LytM185-316 as an antibacterial
agent is a more remote possibility than originally envi-
saged and that efforts to develop antibacterial peptido-
glycan hydrolases should perhaps be concentrated on
proteins that act as bacteriocins rather than autolysins.
Methods
Bacterial cultures
Bacteria were grown in CASO broth (Fluka) at 37°C
with strong aeration from a 100-fold dilution of over-
night cultures. Three strains of S. aureus were used in
the studies. The LS-1 is an arthritogenic strain originally
isolated from swollen mouse joint [39]. The 8325–4
strain is a derivative of NCTC 8325, which has been
cured of resident prophages and has low production of
coagulase and surface adhesions [40]. The P1 strain was
isolated from a rabbit inoculated with ATCC 25923 and
has better adherence than 8325–4 to endothelial cells (a
generous gift from prof. T.J. Foster, Trinity College,
Dublin, Ireland) [41]. The LS-1 strain was used to de-
velop the eczema model, while the P1 strain was used
for a comparison of enzyme efficacies in the eczema
model. Strain 8325–4 was used for all in vitro assays
(pulldown, lysis, stability). The susceptibilities of the
8325–4 and P1 strains towards LytM and lysostaphin
were comparable.
Proteins
A fragment of DNA corresponding to the LytM24-105 pro-
tein was amplified by PCR from the previously described
full length LytM clone [12] inserted into the pET15mod
vector and called pET15modLytM24-105. The construct
coded for the LytM fragment fused to an amino-terminal
histidine tag and could be expressed in soluble form in E.
coli strain BL21(DE3). Protein expression was induced
during the logarithmic growth phase of the bacteria
(OD595 of 0.8) by the addition of 1 mM IPTG and contin-
ued for 4 h at 25°C. The recombinant protein was purified
by affinity chromatography on a Ni2+ loaded, nitrilo-
triacetic acid (NTA) agarose column (Qiagen), followed by
gel filtration on a Sephacryl S-200 column (Amersham
Bioscience). LytM26-316, LytM99-316, LytM185-316 and allpoint mutants were expressed and purified as previously
described [12]. Lysostaphin (mature form) was purchased
from Sigma and used without further purification.
Antibodies
Polyclonal antibodies against LytM185-316 were raised in
rabbit (Pineda Antibody Service, Berlin, Germany). Anti-
body purification was performed by affinity to LytM185-
316 protein coupled to CNBr-activated Sepharose 4B
(Amersham Bioscience) according to the manufacturer’s
instructions. After washing, antibodies were eluted with
100 mM glycine pH 2.7. The pH of the eluent was im-
mediately neutralized by the addition of 1/10 volume of
2 M Tris–HCl pH 8.0. The concentration of the anti-
bodies in the eluent was estimated based on the absorp-
tion at OD280.
Western blot hybridization
Proteins separated by SDS-PAGE were transferred onto
ECL membrane (Amersham Bioscience) by semidry trans-
fer and then incubated with 0.5 μg/ml purified antibodies
against LytM185-316 protein. Goat anti-rabbit peroxidase-
conjugated secondary antibodies (Sigma) were detected
using Western Blot Luminol Reagent (Santa Cruz
Biotechnology).
LytM stability
Supernatants from 1 ml cultures of S. aureus at late ex-
ponential phase were concentrated, mixed with 2 μg of
LytM26-316, and incubated overnight at 37°C. Proteins
were separated on SDS-PAGE and used for Western blot
hybridization. To assess the stability of lysostaphin and
LytM185-316 in buffer with addition of blood or serum
(from rat) enzyme was mixed with 5% or 50% blood or
serum in 50 mM glycine pH 8.0, and incubated at 37°C.
Protein samples were collected after 1 and 4 h, separated
by SDS-PAGE and used for Western blot hybridization.
Cell wall treatment
Late exponential phase cultures of S. aureus grown in
CASO Broth medium were harvested by centrifugation,
resuspended in buffer A (20 mM Tris–HCl pH 7.5) and
autoclaved for 20 min. Crude extract was obtained after
sonicating the cells for 3 min. The accessory wall polymers
were removed by the following methods. SDS treated
walls were boiled in 4% SDS for 30 min. Trypsinized walls
were prepared by 8 h trypsin digest (0.5 mg/ml) at 37°C.
Trichloroacetic acid (TCA) treatment was done by 48 h
incubation in 10% TCA at 4°C. After each of these treat-
ments, cell walls were extensively washed in buffer A.
Purified peptidoglycans were prepared as described previ-
ously [12] by combining all methods described above. Al-
ternatively, S. aureus peptigdoglycan was purchased from
Fluka Biochemika.
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To assess binding, 2 μg of protein was mixed with cell
walls or peptidoglycans (100 μg) and incubated at room
temperature for 15 min. Then, soluble and insoluble
fractions were separated by centrifugation and peptido-
glycans were washed with 1 ml of buffer A. Soluble frac-
tions and washed peptidoglycans were mixed with loading
buffer separated by SDS-PAGE and analyzed by Western
blot hybridization. Final concentrations of 10 mM EDTA,
1 mM 1,10-phenanthroline, 10 mM N-acetylglucosamine,
10 mM glycine hydroxamate, 1 mM PMSF and 1 mM E-64
were used to test the influence of these compounds on pep-
tidoglycan binding.
Cell lysis assay
S. aureus cells collected at the exponential growth phase
were washed and suspended in buffer A supplemented
with 200 μg/ml erythromycin. Then the cells were
diluted to an apparent OD595 of 1.8 with an appropriate
buffer. Enzymes were added to the final concentration of
18nM and 200 μl of reaction transferred onto the microti-
ter plate. Plates were incubated at 37°C with 2 s shaking
every 5 min. OD of the suspension was checked at the
wavelength of 595 nm at 0, 20, 40, 60, 90 or 120 min. after
starting the reaction. Ionic strength of the reaction milieu
(cells resuspended in appropriate buffer) was measured
using conductivity meter MeteLab CDM230 (Radiometer
Analytical, France) at the beginning of the tests. Lytic ac-
tivity was calculated as a per cent of control OD595 (the
same samples as for reaction but without enzymes). Each
experiment was repeated twice in quadruplicate.
Determination of minimal inhibitory concentration (MIC)
and minimal bactericidal concentration (MBC)
Both parameters were determined generally as described
by Kusuma and Kokai-Kun [36]. For MIC determination
by the microdilution method, 100 μl of Cation-Adjusted
Mueller-Hinton broth were inoculated with ~104 S. aureus
cells (strain 8325–4) and enzyme concentrations between
4 and 0.0015 μg/ml were tested. For MBC determination,
~106 CFU/ml of S. aureus cells (strain 8325–4) in either
CASO broth or in 50 mM glycine pH 7.5 were incubated
with between 10 to 0.15 μg/ml of enzyme. For lysostaphin,
but not for LytM, the buffer was supplemented with
150 mM NaCl to make digestion conditions optimal for
the enzyme.
Animal experiments
Ethical permission for animal experiments was obtained
from the Animal Research Ethics Committee of Göteborg
University. Throughout the experiments the animals were
under control of the veterinarian. No differences in animal
behavior and general state of health were observed be-
tween the control and experimental groups.Induction of chronic contact eczema in mice
NMRI mice were sensitized by epicutaneous application
of 150 μl of a mixture of ethanol and acetone (3:1) con-
taining 3% of 4-ethoxymethylene-2-phenyloxazolone
(oxazolone, Sigma) on the abdomen skin. Six days later,
and subsequently every second day, all the mice were
challenged on both sides of one ear with 30 μl 1% oxazo-
lone dissolved in olive oil. The mice received altogether
4 oxazolone challenges on the ear. This procedure leads
to chronic, eczematous skin inflammation characterized
macroscopically by swelling, redness and superficial des-
quamation and microscopically by influx of inflamma-
tory cells (Additional file 4).
Infection kinetics
The day following the last application of oxazolone, the
mice were briefly anaesthetized, and S. aureus in a vol-
ume of 10 μl was spread on the skin surface of the
inflamed ear. In the first experiment four mice with
dermatitis were subjected to skin infection in one ear
while the contra lateral ear was used as a control. S. aur-
eus strain LS-1 at 106, 107, 108, and 109 CFU (colony
forming unit) was spread on each ear, and the mice were
sacrificed two days later. In the second experiment, the
kinetic of infection was assessed. Twenty mice with
dermatitis on one ear were exposed to 106 CFU S. aureus
strain LS-1. Groups of five mice each were sacrificed at
1, 2, 3, and 6 days following exposure to bacteria. One
mouse ear/group was subjected to histological examin-
ation (Additional file 4) and the rest 4 ears/group were
subjected to enumeration of staphylococci.
Comparison of lysostaphin and LytM185-316 in the mouse
model
In the last in vivo experiment the staphylococcal strain
P1 (106/ear) was used to infect ears of mice with eczema.
Twelve hours after inoculation of bacteria the treatment
with proteins was started; 100 μg of lysostaphin or
LytM185-316 in 50 mM glycine pH 8.0 and 10% glycerol
buffer was applied to each mouse ear in a volume of
20 μl. In the case of control mice buffer alone was used
for the treatment. Ears were treated with proteins or
buffer four times every 12 hours. Three hours after the
last treatment mice were anesthetized and the ears dis-
sected. The ears were washed with alcohol to remove
surface bound bacteria, kept on ice, homogenized and
diluted in PBS. One hundred microliter of the homogen-
ate from various dilutions was then transferred to agar
plates, containing 7.5% sodium chloride. After incuba-
tion at 37°C for 24 hours the colony forming units were
counted. 10 mice were used in the control group and in
each treatment group.
Prior to the in vivo use, staphylococci were cultured
for 24 hours on blood agar plates, re-inoculated and
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harvested, and stored frozen at −20°C after suspending
aliquots in phosphate-buffered saline (PBS) supplemen-
ted with 5% bovine serum albumin and 10% dimethyl
sulphoxide. Before application on ears, staphylococcal
suspensions were thawed, bacteria washed in PBS and
diluted in PBS to achieve the appropriate concentration
of the staphylococci. To determine the CFU, aliquots of
staphylococcal suspensions were subjected to dilution,
plating on blood agar and enumeration.
Additional file
Additional file 1: Picture of mouse ears untreated (on the left) and
treated (on the right) with oxazolone.
Additional file 2: Stability of LytM185-316 and lysostaphin. Proteins were
incubated without (1) or with concentrated, conditioned S. aureus media
(2), 5% (4) or 50% (5), blood and 5% (6) or 50% (7) serum. After
incubation proteins were separated by SDS-PAGE electrophoresis and
detected by Western blot hybridization with anti-LytM antibodies.
Additional file 3: Time course of S. aureus 8325–4 cell lysis by
LytM185-316 and lysostaphin in various conditions. (A) Influence of glycine.
Lysis experiments were done in 100 mM glycine-NaOH, pH 8.0, 50 mM
Tris-HCl, pH 8.0 and 100 mM glycine in 50 mM Tris-HCl pH 8.0. (B)
Influence of mono-, di- and triglycine. Buffers were made as 50 mM with
pH adjusted to 8.0 with NaOH. For comparison lysis in dd water was also
checked. (C) Influence of various aminoacids. 50 mM
L-arginine-HCl, D,L-alanine-NaOH, L-arginine-HCl, L-glutamic acid-NaOH,
diaminopimelic acid (DAP)-NaOH of pH 8.0 were tested. Lysis
experiments were performed as described in Material and Methods.
Additional file 4: Histological examination of mouse ear during the
development of eczema and S. aureus infection. (A) section of control
ear, (B) section 2 days after S. aureus infection; massive invasion of
inflammatory cells can be observed (indicated with open arrows).
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